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Background: A recent meta-analysis based on data from > 7,000 pregnancies reported an 
  association between prenatal polychlorinated biphenyl (PCB)–153 exposure and reduced birth 
weight. Gestational weight gain, which is associated negatively with PCB levels in maternal and 
cord blood, and positively with birth weight, could substantially confound this association.
oBjective: We sought to estimate the influence of gestational weight gain on the association 
between PCB-153 exposure and birth weight using a pharmacokinetic model.
Methods: We modified a recently published pharmacokinetic model and ran Monte Carlo simula-
tions accounting for variability in physiologic parameters and their correlations. We evaluated the 
pharmacokinetic model by comparing simulated plasma PCB-153 levels during pregnancy to serial 
measurements in 10 pregnant women from another study population. We estimated the association 
between simulated plasma PCB-153 levels and birth weight using linear regression models.
results: The plasma PCB-153 level profiles generated with the pharmacokinetic model were com-
parable to measured levels in 10 pregnant women. We estimated a 118-g decrease in birth weight 
(95% CI: –129, –106 g) for each 1-μg/L increase in simulated cord plasma PCB-153, compared 
with the 150-g decrease estimated based on the previous meta-analysis. The estimated decrease 
in birth weight was reduced to –6 g (95% CI: –18, 6 g) when adjusted for simulated gestational 
weight gain.
conclusion: Our findings suggest that associations previously noted between PCB levels and birth 
weight may be attributable to confounding by maternal weight gain during pregnancy.
citation: Verner MA, McDougall R, Glynn A, Andersen ME, Clewell HJ III, Longnecker MP. 
2013. Is the relationship between prenatal exposure to PCB-153 and decreased birth weight 
attributable to pharmacokinetics? Environ Health Perspect 121:1219–1224; http://dx.doi.
org/10.1289/ehp.1206457
Introduction
Cord serum levels of PCB‑153, a highly 
  persistent polychlorinated biphenyl (PCB) 
congener, were recently reported to be asso‑
ciated with lower birth weight in a meta‑
analysis of data from > 7,000 pregnancies 
(Govarts et al. 2012). In the meta‑analysis, 
the overall median concentration of PCB‑153 
in cord serum was 0.14 μg/L, and the sum‑
mary estimate suggested a 150‑g decrease 
in birth weight with each 1‑μg/L increase 
in PCB‑153. In light of the evidence that 
reduced birth weight is related to health and 
mortality in later life, these findings may be 
of particular importance for public health. 
However, because gestational weight gain 
is negatively associated with PCB levels in 
maternal and cord blood, and positively associ‑
ated with birth weight, the association may 
be confounded by changes in physiology and 
pharmaco  kinetics during pregnancy rather 
than reflecting a causal effect of PCB exposure.
PCBs are highly lipophilic and conse‑
quently sequester mainly in body lipids. 
Among women whose weight gain during 
pregnancy is within the range recommended 
by the Institute of Medicine, about 30% of 
that weight gain is attributable to an increase 
in body lipids (Butte et al. 2003). For example, 
a 14.4‑kg weight gain during pregnancy was 
associated with an average 4.1‑kg increase in 
body fat (Butte et al. 2003). In the same study, 
gestational weight gain accounted for 58% of 
the variability in fat‑mass gain. Fat gain during 
pregnancy increases the volume of distribu‑
tion of lipophilic chemicals and, as a result, 
dilutes PCB levels in blood lipids (Glynn et al. 
2007). On the other hand, gestational weight 
gain is positively associated with birth weight 
(Siega‑Riz et al. 2009), making this variable a 
potential confounder of the exposure–outcome 
association (Figure 1). The extent to which the 
association between prenatal exposure to PCBs 
and birth weight is attributable to confound‑
ing by gestational weight gain has not been 
adequately considered.
We conducted this study to evaluate the 
influence of maternal and fetal physiology and 
pharmacokinetics on the association between 
prenatal exposure to PCB‑153 and birth 
weight that was reported in the meta‑analysis 
of Govarts et al. (2012). A previously published 
pharmacokinetic model was used to simulate 
changes in PCB‑153 levels during pregnancy 
while accounting for time‑dependent changes 
in physiology, weight gain, and body lipids. 
PCB‑153 was used as a proxy for exposure 
to a mixture of PCB congeners because of its 
long half‑life (Ritter et al. 2011) and its correla‑
tion with other congeners in biologic matrices 
(Gladen et al. 1999; Muckle et al. 2001).
Methods
We assessed the influence of pharmacokinetics 
on the PCB–birth weight relationship with a 
two‑step approach. First, we modified a phar‑
macokinetic model (Verner et al. 2013) to 
run Monte Carlo simulations where exposure 
and physiologic characteristics were varied to 
generate realistic population data. Next, we 
used the simulated population data in linear 
regression analyses to estimate the association 
between simulated PCB‑153 concentrations 
in maternal or cord plasma and birth weight. 
The pharmacokinetic model. The two‑ 
compartment pharmacokinetic model we used 
in this study is detailed by Verner et al. (2013). 
We opted for this simple model instead of 
the more complex physiologically based phar‑
macokinetic (PBPK) model presented by 
Verner et al. (2009) because modifications to 
model variations in pregnancy‑related param‑
eters, including gestational weight gain, were 
straightforward, and it requires less compu‑
tation time. Briefly, this model simulates 
lifetime exposure and bioaccumulation in 
the mother and the fetus. Because PCB‑153 
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partitions almost exclusively in lipids, only 
the lipid fraction of maternal and fetal tissues 
were represented in the model (Figure 2A). 
Maternal weight profiles from birth until 
conception were based on a normal growth 
curve (Kuczmarski et al. 2000) adjusted for 
pre  pregnancy body weight. Corresponding 
changes in body lipids were estimated based on 
body weight profiles and age‑specific percent‑
ages of body fat (International Commission 
on Radiological Protection 2002). The increase 
in maternal lipids during pregnancy was esti‑
mated based on gestational weight gain as 
described below. We modeled changes in fetal 
lipid mass as a function of a normal growth 
profile (Guihard‑Costa et al. 1995) adjusted 
to match birth weight and the percentage of 
lipids at birth (Enzi et al. 1981). An example 
of maternal and fetal lipid profiles during preg‑
nancy is shown in Figure 2B. We assumed 
that PCB‑153 distributes freely and homoge‑
neously in maternal and fetal lipid compart‑
ments, including plasma lipids. PCB‑153 
elimination was parameterized assuming a half‑
life of 14.4 years (Ritter et al. 2011) and that 
elimination was independent of coexposures to 
other environmental contaminants. The com‑
plete model code and script are   provided in 
Supplemental Material.
In their meta‑analysis, Govarts et al. 
(2012) estimated the association between 
birth weight and PCB‑153 levels in cord 
serum (wet‑weight basis). To enable compari‑
son with their results, we expressed lipid‑basis 
levels from the pharmacokinetic model as 
wet‑weight levels in maternal or cord plasma. 
We assumed that plasma and serum PCB‑153 
levels were equivalent because fibrinogen, 
the primary constituent that differs between 
serum and plasma, is unlikely to affect 
PCB‑153 levels substantially. Maternal and 
cord plasma levels were derived by multiply‑
ing simulated PCB‑153 levels in lipids by the 
assumed concentration of lipids in plasma:
Plasma PCB‑153 (μg/L) =  
  Lipid PCB‑153 (μg/g lipids)  
 × Plasma lipids (g/L).  [1]
On average, maternal plasma lipids increase 
linearly during pregnancy, from 4.4 g/L at 
conception to 7.9 g/L at delivery [we aver‑
aged total plasma lipid levels during each tri‑
mester from data of from Aurell and Cramer 
(1966), Chiang et al. (1995), Mazurkiewicz 
et al. (1994), and van Stiphout et al. (1987)]. 
We assumed a cord plasma lipid concentra‑
tion of 1.8 g/L (Denkins et al. 2000) to cal‑
culate cord plasma PCB‑153 levels from fetal 
lipid PCB‑153 at delivery. Average profiles of 
maternal and cord plasma lipids are depicted 
in Figure 2D. An example of maternal plasma 
PCB‑153 profile and cord plasma level at 
delivery is shown in Figure 2E.
Monte Carlo simulations. Each Monte 
Carlo iteration represented an individual to 
Figure 1. Conceptual diagram of the association 
between cord plasma PCB-153 levels and birth 
weight.
Gestational
weight gain
Cord plasma
PCB-153 level
Birth
weight Figure 2. Pharmacokinetic model with homogeneous distribution of PCB-153 across maternal and fetal 
lipids (A). An example of simulated lipid and PCB-153 profiles is presented in B–E for a woman with a 
pre  pregnancy body weight of 60 kg, a gestational weight gain of 12.5 kg, and a 0.5-μg/L plasma PCB-153 
level at conception giving birth to a 3.4-kg girl at 25 years of age: (B) amount of maternal and fetal lipids; 
(C) PCB-153 levels in maternal and fetal lipids; (D) lipid content of maternal and cord plasma; (E) PCB-153 
levels in maternal and cord plasma. The vertical dotted lines represent the time of conception. Because 
cord plasma lipid and PCB-153 levels were estimated only at delivery, single values (dots at 39 gestational 
weeks) are represented (D,E).
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whom physiologic parameters and plasma 
PCB‑153 level at conception were assigned 
(Table 1). Parameters that remained con‑
stant for a given iteration (age at delivery, 
pre  pregnancy body weight, gestational 
weight gain, PCB‑153 half‑life, child sex, 
cord plasma lipid concentration, and plasma 
PCB‑153 level at conception) were sampled 
from published distributions (Table 1). We 
varied parameters that fluctuate within indi‑
vidual iterations (maternal and fetal body lip‑
ids and maternal plasma lipid concentration) 
by multiplying average values by a multiplier 
sampled from a distribution centered around 
one where the standard deviation is equal to 
the reported coefficient of variation (Table 1). 
For example, maternal plasma lipids were 
  calculated as follows:
Maternal plasma lipids (g/L)i = Average 
  maternal plasma lipid concentration  
  × Maternal plasma lipid multiplieri, [2]
where i indexes “subject” (i.e., Monte Carlo 
iteration) and using the coefficient of varia‑
tion calculated based on data from Glynn 
et al. (2011) as the SD of the multiplier 
distribution.
The distribution of maternal plasma 
PCB‑153 level at conception was adjusted to 
yield a distribution of cord plasma levels simi‑
lar to that reported in Govarts et al. (2012). 
We estimated the daily PCB‑153 absorbed 
dose (micrograms per kilogram body weight) 
through an iterative optimization process 
so that exposure to this daily dose over the 
  woman’s lifetime resulted in a simulated blood 
level at conception matching that sampled 
from the distribution. This approach can 
encompass exposure through different routes 
because it is based on internal levels.
We induced correlations between ges‑
tational weight gain and both birth weight 
and maternal lipid gain during pregnancy 
by reconstructing linear regressions derived 
from the Collaborative Perinatal Project 
data (National Institutes of Health 2011) 
or obtained from the article by Butte et al. 
(2003). At each Monte Carlo iteration, a ges‑
tational weight gain was sampled from the 
distribution defined in Table 1 and used to 
estimate birth weight and maternal lipid gain 
based on linear regression equations. We 
replicated the dispersion of residuals in these 
associations by adding a value sampled from 
the residual distributions (Table 1). Not only 
does this approach replicate the correlation 
coefficient, but it also accounts for the slope, 
therefore yielding realistic associations.
The increase in maternal lipids as a func‑
tion of gestational weight gain was estimated 
from a regression based on measurements in 
women between 0 and 36 weeks of pregnancy 
published by Butte et al. (2003):
Maternal lipid gain (kg)i =  
 0.675  × Gestational weight gain (kg)i  
  – 3.89 + Residual lipid gain (kg)i, [3]
where the residual lipid gain (the gain in 
lipids not explained by gestational weight 
gain alone) was sampled from a normal dis‑
tribution centered around 0 and an SD of 
2.69 kg truncated at ± 2 SD, and i indexes 
“subject.” We assumed this relationship to be 
valid beyond 36 weeks of pregnancy. Birth 
weight was simulated based on gestational 
weight gain data from 48,743 mother–infant 
dyads in the Collaborative Perinatal Project 
(Niswander and Gordon 1972):
Birth weight (kg)i = 
  2.982 + 0.02262  
  × Gestational weight gain (kg)i  
  + Residual birth weight (kg)i, [4]
where the residual birth weight (the birth 
weight not explained by gestational weight 
gain alone) was sampled from a normal dis‑
tribution with a mean of 0 and an SD of 
0.49 kg with a minimum of –2.82 and a 
maximum of 2.23.
We used acslX (Aegis Technologies Group, 
Inc., Huntsville, AL, USA) for Monte Carlo 
simulations. Parameters calculated using this 
approach in Monte Carlo simulations accu‑
rately replicated previously reported Pearson’s 
correlation coefficients between gestational 
weight gain and maternal lipid gain [simu‑
lated data = 0.79; Butte et al. (2003) = 0.76] 
and birth weight (simulated data = 0.21; 
Collaborative Perinatal Project = 0.21).
Pharmacokinetic model evaluation. We 
evaluated the pharmacokinetic model by 
comparing simulated blood PCB‑153 levels 
to serial blood PCB measurements in 10 preg‑
nant women from another study population 
who provided blood for PCB measurements 
on multiple occasions between the 9th and 
the 37th week of pregnancy (Glynn et al. 
2011). We performed a total of 5,000 Monte 
Carlo simulations for each woman of the 
Glynn et al. (2011) study by incorporat‑
ing   individual‑specific age at delivery, pre‑
pregnancy body weight and gestational weight 
gain, and randomly sampling other physi‑
ologic parameters from distributions presented 
in Table 1. For each individual woman, we 
calculated the daily PCB‑153 dose (micro‑
grams per kilogram body weight) so the simu‑
lated plasma level matched that measured in 
the first blood sample drawn at 9–13 weeks 
of gestation. The resulting simulated plasma 
PCB‑153 profiles were visually compared with 
subsequent plasma measurements.
In addition, we ran a Pearson correlation 
analysis between simulated gestational weight 
gain and maternal plasma PCB‑153 levels and 
compared the coefficient to the one calculated 
using data on 2,745 pregnant women from 
the Collaborative Perinatal Project whose 
blood was sampled at around 7 months of 
pregnancy (Longnecker et al. 2005). A similar 
correlation coefficient in the Monte Carlo 
simulations and in the Collaborative Perinatal 
Project data would indicate a good represen‑
tation of the impact of gestational weight gain 
on plasma PCB‑153 during pregnancy.
Statistical analyses. From each Monte 
Carlo simulation, estimated plasma PCB‑153 
levels were compiled for each gestational 
month and at delivery. Simulated gestational 
weight gain and birth weight data were also 
compiled for subsequent statistical analyses. 
Data from the Monte Carlo simulations were 
first analyzed by linear regression without 
adjusting for other covariates:
Birth weight (g) =  
  α + β × Plasma PCB‑153 level (μg/L) + ε,
 [5]
Table 1. Parameter distributions used in the Monte Carlo simulations.
Parameter Distribution Mean ± SD Minimum Maximum Reference
Mother
Age at delivery (years) Normal 24.3 ± 6.1 15 41 NIH 2011a
Pre  pregnancy body weight (kg) Normal 59.0 ± 11.6 25 163 NIH 2011
Gestational weight gain (kg) Normal 10.3 ± 4.7 0 44 NIH 2011
Maternal lipids multiplierb Normal 1.00 ± 0.16 0.68 1.32 Borrud et al. 2010
Plasma lipid multiplierb Normal 1.00 ± 0.13 0.72 1.34 Glynn et al. 2011
Half-life PCB-153 (years) Normal 14.4 ± 2.2 10.0 18.8 Ritter et al. 2011
Residual lipid gain (kg) Normal 0.0 ± 2.7 –5.4 5.4 Butte et al. 2003
Infant
Sex Bernoulli (p = 0.5) —
Fetal lipids multiplierb Normal 1.00 ± 0.17 0.66 1.34 Enzi et al. 1981
Cord plasma lipids (g/L) Normal 1.83 ± 0. 24 1.35 2.31 Denkins et al. 2000
Residual birth weight (kg) Normal 0.0 ± 0.5 –2.8 2.2 NIH 2011
Exposure
Maternal plasma PCB-153 at 
conception (ug/L)
Lognormal 0.487 ± 0.412c 0.001 10.000 Govarts et al. (2012)d
aNational Institutes of Health; the Collaborative Perinatal Project. bParameters fluctuating within individual simulations 
(e.g., age-related changes in the amount of maternal lipids) were varied using a multiplier. cArithmetic mean ± SD. dThe 
distribution of maternal plasma PCB-153 levels at conception was adjusted to yield a distribution of cord plasma levels 
similar to that reported by Govarts et al. (2012), i.e., mean ± SD of 0.180 ± 0.157 μg/L.Verner et al.
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where α is the intercept, β is the regres‑
sion coefficient, and ε is the error term. We 
performed a total of 250,000 Monte Carlo 
simulations to estimate the value of β in the 
regression model of Equation 5. We also fit a 
multivariable linear regression model to deter‑
mine whether adjusting for gestational weight 
gain influenced the association between simu‑
lated PCB‑153 levels and birth weight:
Birth weight (g) =  
  α  
 +  β1   ×  Plasma PCB‑153 level (μg/L)  
 +  β2   ×  Gestational weight gain (kg)  
 +  ε. [6]
Statistical analyses were carried out using IBM 
SPSS Statistics 20 (IBM, Armonk, NY, USA). 
Simulations of 1,1-dichloro-2,2-bis(p-
chlorophenyl)ethylene (p,p´-DDE). In addition 
to PCB‑153, Govarts et al. (2012) evaluated 
the association between cord serum p,p´‑DDE 
levels and birth weight. We also performed 
Monte Carlo simulations for p,p´‑DDE to 
evaluate the influence of gestational weight 
gain on the association between cord plasma 
p,p´‑DDE and birth weight. We used the same 
pharmacokinetic model and parameters as 
we used for PCB‑153 (Table 1), except for 
half‑life [mean ± SD = 13 ± 2 years (assuming 
a 15% coefficient of variation) (Wolff et al. 
2000)] and maternal plasma level at concep‑
tion (mean ± SD = 2.099 ± 1.633 μg/L).
Sensitivity analyses. We performed sensi‑
tivity analyses to evaluate the impact of certain 
model assumptions on the results of our study. 
First, our calculation of maternal lipid gain as 
a function of gestational weight gain was based 
on the regression published by Butte et al. 
(2003). In their study, Butte et al. (2003) used 
equations derived from experiments on non‑
pregnant subjects (Fuller et al. 1992) and mea‑
surements taken both before (bone mineral 
content) and during their pregnancy (body 
volume, total body water, and body weight) to 
estimate maternal lipids at different times dur‑
ing pregnancy. Because measurements used 
to estimate maternal lipids during pregnancy 
may conflate both the mother and the fetus, 
it is possible that our estimations of maternal 
lipids during pregnancy were slightly over‑
estimated. To evaluate how this may affect 
our findings, we also performed Monte Carlo 
simulations where estimated fetal lipids were 
subtracted from estimated maternal lipids.
Second, we considered only the correla‑
tions between gestational weight gain and the 
increase in maternal lipids and birth weight. 
Correlations between other parameters may 
also influence the association between PCB‑153 
exposure and birth weight. Of particular inter‑
est are the associations between pre  pregnancy 
body weight and both gestational weight gain 
and birth weight. We ran a sensitivity analysis 
with these additional associations (based on our 
analysis of the Collaborative Perinatal Project 
data) to quantify their impact on our findings. 
Gestational weight gain was first derived from 
pre  pregnancy body weight:
Gestational weight gain (kg)i =  
  11.567 – 0.218  
 ×  Pre  pregnancy body weight (kg)i  
  + Residual gestational weight gain (kg)i, [7]
where the residual gestational weight gain was 
sampled from a normal distribution with a 
mean ± SD of 0.0 ± 4.7 kg. Then birth weight 
was simulated based on both gestational 
weight gain and pre  pregnancy body weight:
Birth weight (kg)i =  
  2.383 + 0.009  
 ×  Pre  pregnancy body weight (kg)i  
  + 0.026 × Gestational weight gain (kg)i  
  + Residual birth weight (kg)i, [8]
where the residual birth weight was sampled 
from a normal distribution with a mean ± SD 
of 0.0 ± 0.5 kg. 
Results
Pharmacokinetic model evaluation. 
Simulated plasma PCB‑153 levels were in 
good agreement with median values measured 
during pregnancy among the 10 women 
included in the Glynn et al. (2011) study 
(Figure 3). Levels reported by Glynn et al. 
(2011) increased from a median of 0.37 μg/L 
at 9–13 weeks of gestation to 0.48 μg/L at 
35–36 weeks. Similarly, simulated plasma 
levels at 35 weeks had a median of 0.45 μg/L. 
The Pearson correlation coefficient between 
simulated gestational weight gain and mater‑
nal plasma PCB‑153 level at 7 months of 
pregnancy (r = –0.15) was comparable to the 
correlation estimated using data from the 
Collaborative Perinatal Project (r = –0.13), 
indicating a good representation of the 
impact of gestational weight gain on plasma 
PCB‑153 during pregnancy.
Association between simulated plasma 
PCB-153 and birth weight. The crude asso‑
ciation between simulated plasma PCB‑153 
levels and birth weight increased in strength 
during pregnancy (Table 2). Maternal plasma 
PCB‑153 levels at the beginning of preg‑
nancy, when gestational weight gain has little 
influence on the dilution of PCBs, showed 
no association with birth weight. However, 
Table 2. Changes in birth weight (g) associ-
ated with a 1-μg/L increase in simulated plasma 
PCB-153 levels from 250,000 Monte Carlo simula-
tions.
Time β (95% CI)a
Maternal plasma
Conception 3.75 (–1.03, 8.53)
1st month –2.54 (–7.01, 1.94)
2nd month –7.79 (–11.99, –3.60)
3rd month –12.22 (–16.17, –8.27)
4th month –16.06 (–19.79, –12.34)
5th month –19.49 (–23.01, –15.97)
6th month –22.49 (–25.83, –19.16)
7th month –25.24 (–28.42, –22.07)
8th month –27.71 (–30.73, –24.69)
Delivery –29.75 (–32.62, –26.88)
Cord plasma
Delivery –117.55 (–129.31, –105.79)
aβ and 95% CI were estimated from linear regression 
models unadjusted for gestational weight gain.
Figure 3. Comparison of simulated plasma PCB-153 levels versus serial plasma measurements in 10 preg-
nant women from another study population. The lines represent the minimum, 25th percentile, median, 
75th percentile, and maximum plasma PCB-153 concentrations predicted from 5,000 Monte Carlo simula-
tions that were carried out for each of the 10 individuals included by Glynn et al. (2011) based on the first 
PCB-153 measurement at 9–13 weeks of gestation. Circles represent the median measured PCB-153 levels 
at different times, and error bars represent the minimum and maximum measured plasma PCB-153 levels 
among the 10 women included by Glynn et al. (2011).
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an association appeared with increasing ges‑
tational weeks that was strongest at deliv‑
ery, resulting in an estimated reduction of 
30 g in birth weight (95% CI: –33, –27 g) 
with each 1‑μg/L increase in PCB‑153 
in maternal plasma. A 1‑μg/L increase in 
PCB‑153 in cord plasma was associated 
with a 118‑g decrease in mean birth weight 
(95% CI: –129, –106 g), which was slightly 
smaller than the 150‑g decrease (95% CI: 
–240, –50 g) estimated based on the meta‑
analysis by Govarts et al (2012). In our analy‑
ses with p,p´‑DDE, we estimated a 31‑g (95% 
CI: –34, –28 g) decrease in birth weight for 
each 1‑μg/L increase in cord plasma level 
compared with the 7‑g decrease (95% CI: 
–18, 4 g) reported by Govarts et al (2012).
The association was similar in sensitiv‑
ity analyses when the estimated volume of 
fetal lipids was subtracted from the esti‑
mated volume of maternal lipids (101‑g 
decrease in birth weight; 95% CI: –112, 
–90 g) and when we accounted for the cor‑
relation between pre  pregnancy body weight 
and gestational weight gain and birth weight 
(125‑g decrease in birth weight; 95% CI: 
–137, –112 g). When we adjusted for ges‑
tational weight gain (Equation 6), the asso‑
ciations were greatly reduced: We estimated 
a 2‑g decrease (95% CI: –4, 1 g) in birth 
weight with each 1‑μg/L increase in PCB‑153 
in maternal plasma at delivery, and a 6‑g 
decrease (95% CI: –18, 6 g) with each 1‑μg/L 
increase in PCB‑153 in cord plasma. The 
effect estimate remained unchanged in the 
regression model of cord plasma PCB‑153 
and birth weight adjusting for age at deliv‑
ery (continuous), pre  pregnancy body weight 
(continuous), and child sex (dichotomous) 
(β: 118 g, 95% CI: –130, –106 g).
Discussion
In this study, we assessed whether the associa‑
tion between cord PCB‑153 levels and birth 
weight reported in a recent meta‑analysis 
(Govarts et al. 2012) might be attributable 
to the influence of gestational weight gain 
on both PCB‑153 levels and birth weight. 
Simulated data generated using a pharmaco‑
kinetic model suggested that the association 
is strongly confounded by gestational weight 
gain, implying that associations between pre‑
natal PCB levels and birth weight that are not 
adjusted for gestational weight gain may be 
biased away from the null.
The negative association between simu‑
lated maternal plasma PCB‑153 levels and 
birth weight increased with gestational weeks. 
The strongest association was at delivery, 
when weight gain was the greatest and con‑
sequently had the largest estimated effect on 
simulated PCB levels. In addition, the nega‑
tive association with birth weight was larger 
for cord plasma levels than maternal levels at 
delivery. This is attributable to the narrower 
range of PCB concentrations in cord blood: 
A 1‑unit change in cord plasma levels repre‑
sents a greater relative increase in exposure 
than a 1‑unit change in maternal plasma lev‑
els. Interestingly, Govarts et al. (2012) also 
found that the estimated association between 
PCB levels and birth weight was larger in 
the studies that measured PCB levels in cord 
blood than in studies where cord serum levels 
were estimated from maternal serum levels 
using conversion factors. The effect estimate 
observed in the present study was comparable, 
although smaller, to the summary estimate 
reported in the meta‑analysis by Govarts et al. 
(2012), which was not adjusted for gesta‑
tional weight gain. Their secondary analyses 
in cohorts where information on gestational 
weight gain was available revealed that adjust‑
ment for this confounder had little influence 
on the effect estimate. In contrast, adjustment 
for gestational weight gain greatly reduced the 
magnitude of the negative association in our 
study. We note that because gestational weight 
gain is not a precise surrogate measure of the 
increased maternal lipids during pregnancy, 
adjustment for it would not be expected to 
completely attenuate an apparent association 
between PCB‑153 levels and birth weight. In 
addition, we would expect that adjustment 
would be more incomplete when gestational 
weight gain is classified based on mothers’ 
recall rather than measured weight gain.
Although our study focused on PCB‑153, 
confounding by gestational weight gain is 
expected to occur for other lipophilic persis‑
tent organic pollutants, such as p,p´‑DDE, 
and polybrominated diphenyl ethers (PBDEs). 
For example, PBDEs have also been associ‑
ated with decreased birth weight (Harley 
et al. 2011). In their study, Harley et al. 
(2011) reported a 140‑g decrease (95% CI: 
–254, –26 g) in birth weight for each 10‑fold 
increase in the sum of PBDEs in maternal 
serum at about 26 weeks of gestation. When 
they adjusted for gestational weight gain, this 
association was reduced to a 99‑g decrease 
(95% CI: –216, 19 g) in birth weight. The 
remaining association, although nonsignificant, 
could indicate that the relationship between 
PBDEs and birth weight is not attributable 
simply to gestational weight gain. Govarts 
et al. (2012) reported a 7‑g decrease (95% 
CI: –18, 4 g) in birth weight for each 1‑μg/L 
increase in cord plasma p,p´‑DDE. The 
authors suggested that the weaker association 
between p,p´‑DDE and birth weight compared 
with PCB‑153 is evidence against gestational 
weight gain being the underlying cause of 
the negative association between PCB‑153 
and birth weight. When we used our phar‑
macokinetic methodology with p,p´‑DDE, 
we also estimated a weaker association than 
that obtained in our analyses with PCB‑153 
(p,p´‑DDE, β: –31, 95% CI: –34, –28, com‑
pared with PCB‑153, β: –118, 95% CI: –129, 
–106). Because we have found similar results 
solely on the basis of pharmacokinetics, it is 
possible that the reported difference in strength 
between PCB‑153 and p,p´‑DDE is attribut‑
able to noncausal factors (e.g., the difference in 
the range of serum concentrations).
Limitations of our study include the 
strong dependence of results on our assump‑
tions regarding the quantitative relationships 
between gestational weight gain and mater‑
nal lipid gain and birth weight in the Monte 
Carlo simulations. Also, the regression of 
maternal lipid gain as a function of gestational 
weight gain estimated by Butte et al. (2003) 
was based on measurements in a sample of just 
63 women. The effect estimates and standard 
error may be different on a population level, 
which would influence the strength of the 
association between gestational weight gain 
and PCB‑153 levels. Nonetheless, the cor‑
relation between gestational weight gain and 
maternal plasma PCB‑153 levels was similar 
for our simulated data and the epidemiologic 
data from the Collaborative Perinatal Project, 
suggesting that this phenomenon was cap‑
tured accurately by the model. Finally, the 
regression between gestational weight gain and 
birth weight in the Collaborative Perinatal 
Project may not be generalizable to the con‑
temporary European population studied by 
Govarts et al. (2012).
Conclusions
Our study suggests that the association 
between prenatal levels of PCBs and birth 
weight may be strongly confounded by the 
effect of gestational weight gain on both 
blood PCB levels and birth weight. Although 
controlling for gestational weight gain in epi‑
demiologic studies of associations between pre‑
natal exposures to lipophilic persistent organic 
pollutants such as PCBs and birth weight is 
important, because gestational weight gain is 
an imprecise measure of the increased maternal 
lipid compartment during pregnancy, such 
adjustment will not completely remove the 
bias. For other epidemiologic associations 
between pollutants and health outcomes 
that may be attributable partly to pharmaco‑
kinetics, an approach such as the one used 
here may provide quantitative insight into its 
  contribution to the relationship.
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